HOOKIPA BIOTECH

... is developing a new class of innovative prophylactic and therapeutic vaccines based on its proprietary Vaxwave® technology.

The Vaxwave® technology is a novel vaccine platform using a replication-defective viral vector for the prevention and treatment of multiple infectious diseases and cancer.

The company has raised a total of € 27 million in equity finance from internationally renowned venture capital investors.

HOOKIPA BIOTECH AG
Helmut-Qualtinger-Gasse 2 /
Staircase 1, 2nd floor
1030 Vienna
Austria
Map

Contact
T: +43 1 890 63 60
F: +43 1 890 63 60 399
office@hookipabiotech.com

www.hookipabiotech.com

Gallery